Estimating the number of droplets and drug particles emitted from MDIs

AAPS PharmSciTech

Volumn 9, Issue 1, 2008, Pages 112-115

  Stein, Stephen W ^a  

^a 3M COMPANY   (United States)

Author keywords

Metered dose inhaler; Number of particles; Size distribution

Indexed keywords

BECLOMETASONE DIPROPIONATE; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; SALBUTAMOL; ANTIASTHMATIC AGENT;

AEROSOL; ARTICLE; DRUG FORMULATION; DRUG RELEASE; METERED DOSE INHALER; MOLECULAR WEIGHT; NEBULIZATION; PARTICLE SIZE; CHEMICAL MODEL; CHEMISTRY; COLLOID; COMPUTER SIMULATION; DRUG SCREENING; METHODOLOGY; MICROFLUIDICS;

AEROSOLS; ANTI-ASTHMATIC AGENTS; COLLOIDS; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; METERED DOSE INHALERS; MICROFLUIDICS; MODELS, CHEMICAL; PARTICLE SIZE;

EID: 44849090657     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-007-9006-8     Document Type: Article

References (14)

1. B. J. Meakin, D. A. Lewis, D. Ganderton, and G. Brambilla. Countering challenges posed by mimicry of CFC performance using HFA systems. In R. N. Dalby, P. R. Byron, S. J. Farr, and J. Peart (eds.), Respiratory Drug Delivery-VII, Serentec, Raleigh, pp. 99-107 (2000).
2. S. W. Stein and P. B. Myrdal. A theoretical and experimental analysis of formulation and device parameters affecting solution MDI size distributions. J. Pharm. Sci. 93:2158-2175 (2004).
3. I. Gonda. Development of a systematic theory of suspension inhalation aerosols-I. A framework to study the effects of aggregation on the aerodynamic behaviour of drug particles. Int. J. Pharm. 27:99-116 (1985).
4. P. H. Howarth. Why particle size should affect clinical response to inhaled therapy. J. Aerosol. Med. 14:S27-S34 (2001).
5. L. Harrison, C. Leach, J. Machacek, J. Vanden Burgt, and J. Vogel. Beneficial effects with reduced particle size and CFC-free extrafine aerosol steroid on lung deposition, absorption, efficacy and safety. Am. J. Respir. Crit. Care. Med. 155:A666 (1997).
6. A. J. Hickey, T. B. Martonen, Y. Yang. Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols. Pharmaceutica Acta Helvetiae. 71:185-190 (1996).
7. C. A. Malton, G. W. Hallworth, J. M. Padfield. The association and particle size distribution of drug and surfactant discharged from a metered-dose inhalation aerosol. J. Pharm. Pharmacol. 34:65P (1982).
8. L. McKenzie, and M. J. Oliver. Evaluation of the particle formation process after actuation of solution MDIs. J Aerosol. Med. 13:59 (2000).
9. T. Hatch, and S. P. Choate. Statistical description of the size properties of non-uniform particulate substances. J. Franklin Inst. 207:369 (1929).
10. W. C. Hinds Aerosol technology: Properties, behavior, and measurement of airborne particles, Wiley, New York, pp. 91-95 (1982).
11. S. W. Stein. Size distribution measurements of metered dose inhalers using Andersen Mark II cascade impactors. Int. J. Pharm. 186:43-52 (1999).
12. J. P. Mitchell, M. W. Nagel, K. J. Wiersema, C. C. Doyle. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: Comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 aerodynamic particle sizer aerosol spectrometerAAPS PharmSciTech [http://www.aapspharmscitech.org] 4(4):54 (2003).
13. USP 26-NF 21. Chapter 601-Physical tests and determinations: Aerosols. United States Pharmacopeia. Rockville: United States Pharmacopeial Convention. 2105-2123 (2003).
14. S. W. Stein, B. J. Gabrio, and T. J. Beck. Evaluation of a new aerodynamic particle sizer spectrometer for MDI size distribution measurements. In R. N. Dalby, P. R. Byron, S. J. Farr, and J. Peart (eds.), Respiratory Drug Delivery-VII, Serentec, Raleigh, pp. 283-286 (2000).